Overview

A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Handok Inc.
National OncoVenture
Collaborators:
CMG Pharmaceutical Co. Ltd
Handok Inc.